Kornimate/medical-research-clean huggingface dataset:
efficacy and analgesic use during the therapy of iatrogenic pneumothorax using pleuralvent™ and chest tube

Conditions: Pneumothorax

Summary: the aim of this clinical trial is to compare the efficiency and analgesic use in the therapy of iatrogenic pneumothorax when using the pleuralvent™ system in comparison with large bore chest tubes (catheter 16f).

rationale: pneumothorax is a common, usually invasively treated, disorder. the usual methods of treatment are needle aspiration (14-16 g needles) or chest drainage (16+ f catheters). a third therapeutic option is the use of small calibre catheters (\< 16f). according to some studies, the success rates of these methods are comparable. these catheters have the same success rate as large bore chest tubes and treatment with them is less painful for patients. the use of heimlich valves allows for increased patient mobility - or even out-patient treatment. according to a review by the european respiratory society, nowadays there is an availability of systems which are part of advanced intervention techniques. these devices are designed for ease of insertion allowing for the full mobility of patients. it is, however, not clear whether treatment with these new systems is less painful. the aim of this clinical trial is to compare the efficiency and analgesic use in the therapy of iatrogenic pneumothorax when using the pleuralvent™ system in comparison with large bore chest tubes (catheter 16f). process: following the completion of the initial screening (fulfilling of both inclusion and exclusion criteria) and the signing of informed consent, a patient with iatrogenic pneumothorax (pno) will be treated with, according to randomisation, either the pleuralvent™ system or with a large bore chest tube - 16f. a control chest x-ray will be performed immediately after the introduction of the therapeutic method and following 3 days of therapy. if no signs of pno are present, the therapy will be terminated. in cases where the lung will not be completely expanded, the control x-ray will be repeated on the 5th, 7th and 10th day of therapy. if, following this, the pno will persist without resolution, the therapy will be declared non-effective and other therapy modes will be used (conversion to large bore chest drainage in the pleuralvent™group and surgical treatment in the chest drainage group).

Eligibility criteria:
inclusion criteria: * iatrogenic pneumothorax indicated for invasive therapy exclusion criteria: * chronic analgesic therapy * contraindications for pleuralvent™ use * non-compliance of patients * clinically significant hepatopathy (alanine aminotransferase (alt), aspartate aminotransferase (ast) \> 3 times normal values) * clinically significant renal insufficiency (glomerular filtration \< 0.5 ml/kg/min) * allergy to metamizole/tramadol

Keywords: pneumothorax iatrogenic chest tube pleuralvent
influence of original native tricuspid valve lesion (stenosis or steno-insufficiency or insufficiency) on post-implant structural bioprosthetic degeneration after tricuspid valve replacement.

Conditions: Degeneration of Tricuspid Surgical Bioprosthesis

Summary: the structural deterioration process of the implanted bioprosthesis in tricuspid position for tricuspid valve pathology is gradual and irreversible and includes many changes, such as pannus growth, leaflet fibrosis and calcification, delamination of the connective tissue, ruptures and perforations of leaflets. in the great majority of cases svd consists of leaflet calcium deposits and can be clinically associated with young age, hypercholesterolemia, hypertension, diabetes mellitus, renal failure. the long term durability of these bioprosthesis is still missing.

it is not clear if the same biochemical, hemodynamic and immunological mechanisms leading to native valve calcification can cause bioprosthetic svd. we hypothesize that the mechanisms protecting the native valve from calcification in the insufficiency disease may subsequently protect also the bioprosthetic valve from calcific svd. in such a case, considering also the reduced incidence in insufficiency patients of prosthesis-patient mismatch, supposedly associated with increased risk of svd, indication for bioprosthetic valve use could be expanded in patients with insufficiency. because of the rising demand of bioprosthetic valve implantation, even a few years increase in the expected durability of the bhv, although limited to a defined population of patients, will have a very relevant clinical impact. we aim to perform a retrospective, multi-center, observational study. all patients undergoing elective tricuspid valve replacement from 2000 to 2020 who met the inclusion criteria for the study (described in the dedicated section) will be enrolled in the study. these patients will be followed-up as part of routine care, and information about the clinical status, nyha functional class, possible rehospitalization, possible cardiovascular events and postoperative echocardiography will be available for analysis. once consent is given, and if required by local governance, pre-, intra- and post-operative data will be collected in a dedicated, structured, database.

Eligibility criteria:
inclusion criteria: - age ≥ 18 years; 6 - patients who underwent isolated tricuspid valve replacement for stenosis, regurgitation or steno-regurgitation - signed informed consent, inclusive of release of medical information where required by local governance. exclusion criteria: * tricuspid valve replacement associated with other surgical procedures (cabg or other) previous cardiac surgery of any kind; - surgery for acute endocarditis - participation in another clinical trial that could interfere with the endpoints of this study. - pregnant or breastfeeding at time of screening.

Keywords: tricuspid valve tricuspid bioprosthesis durability
diabetic retinopathy vitrectomy study (drvs)

Conditions: Diabetic Retinopathy; Retinal Detachment; Vitreous Hemorrhage

Summary: to compare two therapies, early vitrectomy and conventional management, for recent severe vitreous hemorrhage secondary to diabetic retinopathy. conventional management includes vitrectomy if hemorrhage fails to clear during a waiting period of 6 to 12 months or if retinal detachment involving the center of the macula develops at any time. to compare early vitrectomy and conventional management in eyes that have good vision but a poor prognosis because they are threatened with hemorrhage or retinal detachment from very severe proliferative retinopathy. to study the natural history of severe proliferative diabetic retinopathy.

vitrectomy may not only remove vitreous hemorrhage but also prevent or relieve traction on the retina from contraction of the fibrovascular membranes that characterize severe proliferative diabetic retinopathy. it is important to determine whether early intervention with vitrectomy has a better visual outcome or instead produces a rate of serious complications higher than the rate associated with conventional management. two randomized trials were carried out in the drvs among patients ages 18 to 70 years who had either insulin-dependent or non-insulin-dependent diabetes. in the first trial, the 616 patients who were recruited had severe visual loss from recent severe vitreous hemorrhage in at least one eye. eligible eyes were randomly assigned either to early vitrectomy or to conventional management. in the conventional management group, vitrectomy was carried out 1 year later if hemorrhage persisted; vitrectomy was carried out sooner if retinal detachment -involving the center of the macula occurred. in the second trial, 381 patients were recruited, all of whom had severe fibrovascular proliferations and useful vision in at least one eye. eligible eyes were assigned either to early vitrectomy or to conventional management. conventional management included photocoagulation when indicated, with vitrectomy if a severe vitreous hemorrhage occurred and failed to clear spontaneously during a 6-month waiting period or if retinal detachment involving the center of the macula -occurred. after randomization and treatment, all patients were examined at 6-month intervals for 2 years and annually thereafter. comparisons of visual acuity distributions between experimental and control groups were made.

Eligibility criteria:
men and women eligible for the vitreous hemorrhage group had at least one eye with recent severe vitreous hemorrhage (within 5 months) and visual acuity of 5/200 or less. patients eligible for the "very severe proliferative retinopathy with useful vision" group had extensive active fibrovascular proliferations and visual acuity of 10/200 or better.
developing interview questions to estimate workplace exposure to electric and magnetic fields

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: electric and magnetic fields may increase the risk of cancer. developing interview questions that accurately estimate a person's exposure to electric and magnetic fields may help doctors learn about the long-term effects of workplace exposure. purpose: this clinical trial is developing interview questions that can be used in estimating workplace exposure to electric and magnetic fields.

objectives: * validate an interview-based electric and magnetic field exposure (emf) assessment algorithm against measurements of the time-weighted average magnetic field magnitude used in previous epidemiologic studies. * calibrate the parameters in the algorithm in order to improve the exposure estimates. * correlate emf exposure estimates from the algorithm with biologically based metrics measured by new instrumentation. outline: participants respond to questions during a 5- to 15-minute telephone interview concerning workplace exposure to electric and magnetic (emf) fields. data is collected during the interview using an exposure assessment algorithm designed to estimate emf workplace exposure based on participants' responses. the interview-based estimates are then validated against actual field measurements of magnetic field exposure captured by emdex multiwave monitors located at participating sites.

Eligibility criteria:
disease characteristics: * meets 1 of the following occupation criteria: * three occupations that primarily work in offices at lawrence livermore national laboratories (llnl) * three occupations that do nonelectric manual work (e.g., machinists and laborers) at llnl patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: brain tumor
hpl program for geriatric patients' at risk for stroke

Conditions: Health-Related Behavior

Summary: stroke is a highest reason of illness and death all over world. in 2017, stroke was the second greatest recurrent reason of mortality, after ischemic cardiac illness, and produced 6.2 million mortality all over world. the load of stroke does not only lie in the great mortality but the great morbidity also results in up to 50% of survivors being chronically disabled. thus stroke is a disease of huge public health importance with economic and social consequences.

patients with stroke with uncontrolled glucose levels have higher mortality and poor post stroke outcomes. controlling diabetes and other associated risk factors are effective ways to prevent initial strokes as well as stroke recurrence. diabetes increases ischemic stroke incidence in all age groups, individuals with diabetes are more likely to suffer from hypertension, myocardial infarction and high cholesterol than individuals without diabetes have been linked to a greater risk of stroke. smoking is a major cause of cardiovascular disease and causes one of every four deaths from cardiovascular disease. smoking can raise triglycerides (a type of fat in your blood), lower "good" cholesterol (high-density lipoprotein), make blood sticky and more likely to clot, which can block blood flow to the heart and brain, damage cells that line the blood vessels, increase the buildup of plaque (fat, cholesterol, calcium, and other substances) in blood vessels and cause thickening and narrowing of blood vessels.the idea of lifestyle includes a broad variety of subjects, containing substantial life, spiritual life and other issues. physical activity, smoking, alcohol consumption, nutrition and other aspects to measure lifestyle used by chinese scientists. health promoting lifestyle (hpl) is defined as "a multi-dimensional pattern of self-initiated actions and perceptions that serve to maintain or enhance the level of wellness, self-actualization, and fulfillment of the individual". it assesses a personal well-being activity that involves physical activity, dieting, spiritual growth, interpersonal relationships, health responsibility, and stress management, and would lead to enhaning wellbeing condition

Eligibility criteria:
inclusion criteria: * age 60 years and more * diagnosed with hypertension, diabetes mellitus and cardiac diseases. * able to communicate with health team, free from mental problems, and agreed to participate in the study were included. exclusion criteria: * unable to communicate with health team. * free from mental problems.
knowledge, attitudes and practices of paediatric cardiologists about cardiac rehabilitation in children with congenital heart disease

Conditions: Physician's Role

Summary: despite significant clinical benefits and recommendations of clinical practice guidelines to refer patients for exercise and physical activity counselling in the capacity of cardiac rehabilitation (cr), cr is largely underutilised and not implemented effectively. studies have reported that the reasons for the low implementation of cr are multifactorial at the healthcare system, physician and patient levels. therefore, the aim of this study was to investigate the knowledge, attitudes and practical applications of paediatric cardiologists regarding cardiac rehabilitation and specifically exercise and physical activity in children with congenital heart disease (chd).


Eligibility criteria:
inclusion criteria: * to be a paediatric cardiologist, * providing active service in patient diagnosis and treatment exclusion criteria: * not providing active service in patient diagnosis and treatment despite being a paediatric cardiologist (administrative position, etc.).
examination of serum progesterone levels in an ivf population following two types of egg aspiration

Conditions: Infertility, Female

Summary: the purpose of this study is to determine whether progesterone hormone levels differ following egg retrieval with a single lumen needle compared with a double lumen needle. these levels will be measured on several days before and after egg retrieval. the progesterone levels in each ivf group will also be compared to the group of women who are having iui. in addition, these progesterone levels will be correlated with pregnancy outcomes.

this is a prospective randomized trial consisting of 3 groups of patients. following a long lupron protocol ivf cycle there is a need for supplemental progesterone. the purpose of this study is to determine what range of serum levels should be observed when differing methods of egg aspiration have been administered and whether or not there is a correlation with outcomes or pregnancies.

Eligibility criteria:
inclusion criteria: * ages between 21-37 * cycle day 3 fsh between 2-12 * history of regular menstrual cycles between 24-34 days exclusion criteria: * previous ivf failure * severe male factor * severe obesity, bmi \> 40 * more than 20 follicles on ultrasound prior to retrieval

Keywords: infertility
post-operative treatment with ketorolac after abdominal myomectomy

Conditions: Febrile Morbidity; Pain

Summary: the purpose of this study is to determine if ketorolac, given after abdominal myomectomy, will decrease the frequency of post-oerative fevers as well as improve post-operative pain management.


Eligibility criteria:
inclusion criteria: * ant patient undregoing abdominal myomectomy exclusion criteria: * patients with contraindication to nsaids including history of peptic ulcer disease, renal disease, bleeding diathesis, or hypersensitivity to nsaids

Keywords: post-operative febrile morbidity post-operative pain management
enteroprotein modified fast ( emf )

Conditions: Obesity

Summary: the purposes of the esperience is: 1. to verify the safety of protein sparing modified fast(psmf) by enteral route ( emf )performed in cycles of ten days/months for six months 2. to compare emf with oral psmf clinically ( appetite control, fat freemass mantainance, polmonary function tests and metabolic pattern) 3. to verify the weight mantainance after 6 months from the treatment suspension

rationale a) primary endpoint 1. to verify the safety of protein sparing modified fast by enteral route ( emf )in cycles of ten days/months repeated for six months, 2. to compare emf with oral psmf clinically ( appetite control, polmonary function tests and metabolic pattern) and on metabolic parameters (hypertension, glucose intolerance, dyslipidaemia) maintaining body composition (particularly fat free mass and muscular strength) in 15 patients with disease-causing obesity not responding to medical treatment and/or cognitive/behavioural therapy, who are candidates for invasive treatment such as the gastric balloon or surgery but do not intend to undergo them compared with 15 undergoing the same regimen without the naso-gastric tube. to verify the effects of treatment with regard to the enteral-hormonal structure during the acute phase (selected sub-group) and while undergoing treatment. b) secondary endpoints: 1. to verify the percentage of patients who maintain the weight reached 6 months after stopping treatment with the naso-gastric tube associated with a high-calorie normal-protein diet. 2. verify clinical safety of en in these patients.

Eligibility criteria:
inclusion criteria: * both genders, outpatients * aged between 16 and 75 * with bmi 30 - 45 kg/m2 * that are not in a restricted diet since at least 3 months * with obesity related comorbidities (- type 2 diabetes * mild or moderate osas * orthopedic diseases (coxarthrosis, gonarthrosis) * hypertension * non alcoholic hepatic steatosis * accepting to be enrolled in the study (signing informed consent) exclusion criteria: * presence of gastrointestinal diseases * presence of cancer * patients treated with gastrolesive or anticoagulant drugs * hepatic failure, renal failure or multi-organ failure (cut off) * contraindications for enteral nutrition,mechanical bowel complete, or partial chronic obstruction * severe mesenteric ischemia not caused by hypovolemia * digiunal or ileal fistula with high output (400 ml/die) * severe modifications of the intestinal function caused by enteropathies or insufficient absorbent surface, to the point that a normal nutritional state cannot be maintained * type 1 diabetes * type 2 diabetes treated with oral or injected drugs that may cause hypoglycemia * anbn: anorexia or bulimia nervosa, evaluation of other symptoms by specific tests * patients with major psychiatric disorders or not cooperative, or with alcohol or drug addiction disorders.

Keywords: obesity psmf ( protein sparing modified fast) enteral nutrition tube feeding vlcd ( very low calorie diet) pulmonary function tests body composition ffm ( fat free mass) body fat handgripstregth
comparative efficacy of buprenorphine transdermal patch versus tramadol in postoperative analgesia for shoulder arthroscopy

Conditions: Postoperative Pain; Shoulder Pain; Opioid Analgesia; Tramadol; Buprenorphine; Arthroscopy; Interscalene Brachial Plexus Block; Analgesic

Summary: this study compares the efficacy, safety, and patient satisfaction of the buprenorphine 10 mg transdermal patch versus tramadol for postoperative analgesia in shoulder arthroscopic surgery. the study hypothesizes that buprenorphine provides superior pain relief with fewer side effects compared to tramadol.


Eligibility criteria:
inclusion criteria: * adults aged 18 to 65 years. * patients undergoing elective shoulder arthroscopy. * classified as asa (american society of anesthesiologists) physical status i or ii. * able to provide informed consent. * willing to comply with study protocols and follow-up assessments exclusion criteria: * known allergy or hypersensitivity to buprenorphine, tramadol, or any related compounds. * history of substance abuse, opioid dependency, or chronic pain requiring ongoing analgesic therapy. * pregnant or breastfeeding individuals. * presence of severe hepatic, renal, or respiratory disease. * any psychiatric or neurological condition that might interfere with pain perception or reporting (e.g., dementia, severe anxiety). * participation in another clinical trial within the last 30 days. * inability to apply or tolerate a transdermal patch (e.g., due to skin disorders or sensitivities). * contraindications to interscalene brachial plexus block, such as infection at the site, coagulopathy, or pre-existing neuropathy in the upper limb.

Keywords: buprinorphin transdermal tramadol
effect of different final irrigation protocols on postoperative endodontic pain in devital teeth

Conditions: Postoperative Pain; Endodontically Treated Teeth

Summary: the purpose of this randomized clinical trial was to evaluate the incidence of postoperative pain after root canal treatment using different final irrigation protocols. patients whom need root canal treatment for first time were included. the presence of postoperative pain was assessed after root canal treatment cases at 12, 24, 48, 72 hrs and 1 week.

the aim of this clinical study was to evaluate the intensity and duration of postoperative pain following different final irrigation procedures. patients who have asymptomaticdevital teeth required endodontic treatment were included in this study and routine root canal treatment procedure was applied to these teeth. all of the patients have been recruited from the istanbul medipol university dental clinics in istanbul. ninety asymptomatic teeth were randomly participated into 3 treatment groups in terms of intracanal medicament applied. the presence of postoperative pain was assessed after 12, 24, 48, 72 hrs and 1 week. postoperative pain was recorded by each patient by using visual analogue pain scale. before the treatments, the nature of the study, complications and associated risks were totally explained and written informed consent was obtained from all study participants. the patients were offered local anesthetic before the treatment start. the routine root canal treatment procedure was applied. different final irrigation solutions applied in accordance to the manufacturers' instructions. at the end of treatment, each patient was given an evaluation sheet, explained the treatment procedure and using of visual analogue pain scales, and informed to be returned during the following one week. after one week the teeth was examined according to for pain intensity, percussion \& palpation sensitivity, swelling, analgesic intake and clinical status.

Eligibility criteria:
inclusion criteria: -patients who were healthy volunteers and who have devital premolar and molar teeth with pai 3-5score requiring root canal treatment for first time. patients who were not included the study who; * were pregnant or breast feeding during the duration of the study, * have systemic disease, have any pain and/or any facial swelling, abscess, * were immunocompromised, * were under 18 yrs. and over 65 yrs. age, * were taking antibiotics or corticosteroids within previous three days, * have multiple teeth that required root canal treatment at the same time period; for eliminating pain referral, * have root canals that could not be well-treated with orthograde root canal treatment. exclusion criteria: -the patients who forgot to fill out the form and took antibiotics and/or analgesics right after the first appointment of the therapy were excluded from the study.

Keywords: endodontics postoperative pain visual analogue pain scale